Sandra Rebouissou

List of Publications by Year
in descending order

48	9,002	109137 35	205818 48
papers	citations	h-index	g-index

50	50	50	10758
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. Lancet Oncology, The, 2022, 23, 161-171.	5.1	36
2	Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. Journal of Hepatology, 2021, 74, 1155-1166.	1.8	54
3	Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer. Cancer Discovery, 2021, 11, 2524-2543.	7.7	41
4	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. Hepatology, 2020, 71, 164-182.	3.6	129
5	Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas. Gut, 2020, 69, 1667-1676.	6.1	17
6	Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ERÎ± and HNF1Î±. Cancers, 2020, 12, 2213.	1.7	4
7	Advances in molecular classification and precision oncology in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 215-229.	1.8	311
8	Dual Targeting of Histone Methyltransferase G9a and DNAâ€Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. Hepatology, 2019, 69, 587-603.	3.6	81
9	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Gastroenterology, 2019, 157, 760-776.	0.6	141
10	The role of telomeres and telomerase in cirrhosis and liver cancer. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 544-558.	8.2	154
11	Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by Î²-Catenin Mutations. Cell Metabolism, 2019, 29, 1135-1150.e6.	7.2	92
12	APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. OncoImmunology, 2019, 8, e1583547.	2.1	31
13	Recurrent activating mutations of PPARÎ³ associated with luminal bladder tumors. Nature Communications, 2019, 10, 253.	5.8	44
14	Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. Hepatology, 2018, 68, 964-976.	3.6	43
15	Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro. Clinical Cancer Research, 2017, 23, 4364-4375.	3.2	57
16	A phosphokinomeâ€based screen uncovers new drug synergies for cancer driven by liverâ€specific gain of nononcogenic receptor tyrosine kinases. Hepatology, 2017, 66, 1644-1661.	3.6	15
17	Molecular Classification of Hepatocellular Adenoma AssociatesÂWith Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology, 2017, 152, 880-894.e6.	0.6	290
18	Reply. Hepatology, 2017, 66, 2093-2094.	3.6	1

#	Article	IF	Citations
19	Note of caution: Contaminations of hepatocellular cell lines. Journal of Hepatology, 2017, 67, 896-897.	1.8	37
20	Genotypeâ€phenotype correlation of CTNNB1 mutations reveals different ÃŸâ€catenin activity associated with liver tumor progression. Hepatology, 2016, 64, 2047-2061.	3.6	222
21	Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers. Molecular and Cellular Oncology, 2015, 2, e999507.	0.3	1
22	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nature Genetics, 2015, 47, 505-511.	9.4	1,372
23	NRF2/KEAP1 and Wnt/Î²â€catenin in the multistep process of liver carcinogenesis in humans and rats. Hepatology, 2015, 62, 677-679.	3.6	20
24	A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis. Cancer Research, 2015, 75, 4042-4052.	0.4	96
25	Abstract 2973: Exome sequencing of 243 liver tumors identifies new mutational signatures and potential therapeutic targets. , 2015, , .		0
26	Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes. Cell Reports, 2014, 9, 1235-1245.	2.9	181
27	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Science Translational Medicine, 2014, 6, 244ra91.	5.8	304
28	PI3K/AKT pathway activation in bladder carcinogenesis. International Journal of Cancer, 2014, 134, 1776-1784.	2.3	74
29	Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. Journal of Hepatology, 2013, 58, 350-357.	1.8	146
30	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. Gastroenterology, 2013, 145, 176-187.	0.6	302
31	CDKN2A homozygous deletion is associated with muscle invasion in FGFR3â€mutated urothelial bladder carcinoma. Journal of Pathology, 2012, 227, 315-324.	2.1	90
32	HNF1Î± inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines. BMC Cancer, 2011, 11, 427.	1.1	35
33	Loss of hepatocyte nuclear factor 1Î± function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology, 2010, 51, 557-566.	3.6	66
34	Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature, 2009, 457, 200-204.	13.7	437
35	MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology, 2008, 47, 1955-1963.	3.6	634
36	Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. Journal of Hepatology, 2008, 48, 163-170.	1.8	235

#	Article	IF	Citations
37	The Î²-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. Journal of Hepatology, 2008, 49, 61-71.	1.8	87
38	HNF1Î± Inactivation Promotes Lipogenesis in Human Hepatocellular Adenoma Independently of SREBP-1 and Carbohydrate-response Element-binding Protein (ChREBP) Activation. Journal of Biological Chemistry, 2007, 282, 14437-14446.	1.6	123
39	Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology, 2007, 45, 42-52.	3.6	1,034
40	Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology, 2007, 46, 740-748.	3.6	554
41	Genotype phenotype classification of hepatocellular adenoma. World Journal of Gastroenterology, 2007, 13, 2649.	1.4	90
42	Genotypeâ€“phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC. Hepatology, 2006, 43, 515-524.	3.6	733
43	Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy. European Journal of Cancer Prevention, 2005, 14, 531-540.	0.6	91
44	Germline hepatocyte nuclear factor 1Î± and 1Î² mutations in renal cell carcinomas. Human Molecular Genetics, 2005, 14, 603-614.	1.4	109
45	Mutation of TP53 gene is involved in carcinogenesis of hepatic undifferentiated (embryonal) sarcoma of the adult, in contrast with Wnt or telomerase pathways: an immunohistochemical study of three cases with genomic relation in two cases. Journal of Hepatology, 2005, 42, 424-429.	1.8	32
46	Clinical, Morphologic, and Molecular Features Defining So-Called Telangiectatic Focal Nodular Hyperplasias of the Liver. Gastroenterology, 2005, 128, 1211-1218.	0.6	207
47	Mutation of TCF1 encoding hepatocyte nuclear factor 1Î± in gynecological cancer. Oncogene, 2004, 23, 7588-7592.	2.6	21
48	Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. Journal of Hepatology, 2004, 41, 292-298.	1.8	126